Forodesine is a purine nucleoside analog and purine nucleoside phosphorylase (PNP) inhibitor (IC50s = 1.19, 0.48, 1.24, 0.66, and 1.57 nM for human, mouse, rat, monkey, and dog PNP, respectively).1 It inhibits phytohemagglutinin A-, mixed lymphocyte reaction-, or IL-2-induced proliferation of isolated human peripheral blood lymphocytes (PBLs; IC50s = <0.1-0.38 ?M) in the presence, but not absence, of 2’-deoxyguanosine (dGuo). Forodesine inhibits proliferation of CEM-SS T cell acute lymphoblastic leukemia (T-ALL) cells.2 In vivo, forodesine (10 mg/kg) prolongs survival in the hu-PBL-SCID mouse model of xenogeneic graft versus host disease (GVHD).1
1.Bantia, S., Miller, P.J., Parker, C.D., et al.Purine nucleoside phosphorylase inhibitor BCX-1777 (immucillin-H)-a novel potent and orally active immunosuppressive agentInt. Immunopharmacol.1(6)1199-1210(2001) 2.Al-Kali, A., Gandhi, V., Ayoubi, M., et al.Forodesine: Review of preclinical and clinical dataFuture Oncol.6(8)1211-1217(2010)